Hemogenyx Pharmaceuticals PLC Announces Director/PDMR Shareholding finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
TRADING UPDATES: Pelatro gets contracts; Futura raises GBP10 million
Mon, 17th May 2021 15:04
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Pelatro PLC - London-based marketing software specialist - Secures several contracts for change requests, worth around USD300,000, that will be delivered in 2021. With these, the total value of contracts in hand representing 2021 revenue is around USD6.8 million. Comes around a month after firm reports getting several contracts for change requests, adding up to USD500,000, that brought total value of work in hand for 2021 revenue to USD6.5 million. Given that we have clear visibility with contracts secured for USD6.8 million of revenue for 2021 so early in the year, together with the momentum we are building in our business, we are looking forward to a successful outcome this year in line with expectations, says Chief Executive & Managing
Hemogenyx Pharmaceuticals PLC announces Publication of Supplementary Prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
LONDON, UK / ACCESSWIRE / May 12, 2021 / Hemogenyx Pharmaceuticals plc ( Hemogenyx Pharmaceuticals or the Company )(LSE:HEMO) announces that it has today published a supplementary prospectus approved by the FCA (the
Supplementary Prospectus ). The Supplementary Prospectus is a regulatory requirement under the Prospectus Regulation Rules following the publication of the annual report and audited financial statements for the financial year ended 31 December 2020 by the Company.